SynthesisFrontiers in oncology2022
Association Between Metabolic Syndrome and Risk of Renal Cell Cancer: A Meta-Analysis.
Synthesis in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 4 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- Metabolic Syndrome and Obesity-related cancer Risk and Survival: An Umbrella Review of Systematic Reviews With Meta-analysis of Observational Studies.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026Pooled it
- Metabolic syndrome and increased susceptibility to renal cell carcinoma - a meta-analysis.BMC nephrology · 2025Pooled it
- Metabolic syndrome and survival of patients with hepatocellular carcinoma: A meta-analysis.Frontiers in oncology · 2023Pooled it
- Glycemic variability and the risk of atrial fibrillation: a meta-analysis.Frontiers in endocrinology · 2023Pooled it
- Joint effects and dynamic trajectories of metabolic insulin resistance and systemic inflammation in the risk of renal cell carcinoma: a UK Biobank cohort analysis.World journal of urology · 2026Article
- Impact of metabolic syndrome and its components on the tumor aggressiveness of renal cell carcinoma.Medicine · 2026Observational
- Metabolic Risk Factors at the Time of Cancer Diagnosis in Primary Care: A Cross-Sectional Study.Cureus · 2025Article
- Oncological Outcomes of Non-clear Cell Renal Cell Carcinomas: A Retrospective Study From a Tertiary Care Center.Cureus · 2025Article
- TFE3-rearranged RCC with osseous metaplasia found on bone mass densitometry.Annals of medicine and surgery (2012) · 2024Article
- Association between metabolic syndrome and kidney cancer risk: a prospective cohort study.Lipids in health and disease · 2024Article
- Hypertension and hyperglycaemia are positively correlated with local invasion of early cervical cancer.Frontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic syndrome (MetS) has been related to increased risks of a variety of cancers. However, the association between MetS and the risk of renal cell cancer (RCC) remains not fully determined. This meta-analysis was conducted to investigate whether MetS is independently associated with the risk of RCC in adults. Methods: Relevant observational studies were obtained by searching PubMed, Embase, Cochrane's Library, and Web of Science databases. Study characteristics and outcome data were extracted independently by two authors. The random-effect model was used for meta-analysis considering the possible influence of between-study heterogeneity. Predefined subgroup analyses were used to evaluate the possible influences of study characteristics on the outcome. Results: Eight studies involving 10,601,006 participants contributed to the meta-analysis. Results showed that MetS was independently associated with a higher risk of RCC in adult population (risk ratio [RR]: 1.62, 95% confidence interval [CI]: 1.41 to 1.87, p<0.001; I Conclusions: MetS may be independently associated with RCC in adult population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.